GS vs MIRM · P/E 20, rev $37.56B vs rev $336.1M
Goldman Sachs Group Inc (GS) versus Mirum Pharmaceuticals Inc (MIRM) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Mirum Pharmaceuticals Inc (MIRM) is a biotechnology company listed on NASDAQ.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Latest reported MIRM revenue for 2026-06-30 was $336.1M. Net income was -$857.4M. MIRM currently screens at market cap $6.22B.
GS currently screens at market cap $324.25B and trailing P/E 20.1. MIRM currently screens at market cap $6.22B.
Not investment advice. Open the GS and MIRM stock pages for the full models.
Not investment advice.